Phil Taylor

Pfizer and Eli Lilly have inched closer to getting their NGF blocker tanezumab to the filing stage as an alternative to opioids for chronic pain.

Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.

Amid high expectations, the first clinical data with Merck & Co’s STING agonist at ESMO has proved a disappointment—at least as a monotherapy.

Despite the focus on immuno-oncology right now, Deciphera has data showing there is still plenty to talk about when it comes to kinase inhibitors.

Four years ago, J&J splashed out $1.75 billion to take control of antiviral firm Alios, but the lead drug from that deal now seems to be in trouble.

Eiger has given up on one of its rare disease candidates after a second negative trial, but a win for another drug has softened the blow.

Seeking further returns from Taiho Ventures, Taiho Pharma just decided to multiply its investment pool sixfold to $300 million.

Alnylam says it will have to wait for the final results of a phase 3 trial of acute hepatic porphyria drug givosiran before filing.

Ziopharm has scaled back an alliance with Intrexon unit Precigen in oncology and will now focus solely on a pair of T cell receptor technologies.

Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.